The estimated Net Worth of Norbert W Bischofberger is at least $23.2 Milión dollars as of 27 June 2024. Dr Bischofberger owns over 615,518 units of Kronos Bio stock worth over $10,368,972 and over the last 21 years he sold KRON stock worth over $12,192,472. In addition, he makes $596,365 as Pres a CEO & Director at Kronos Bio.
Dr has made over 49 trades of the Kronos Bio stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 615,518 units of KRON stock worth $732,466 on 27 June 2024.
The largest trade he's ever made was buying 3,005,122 units of Kronos Bio stock on 10 June 2024 worth over $3,125,327. On average, Dr trades about 84,160 units every 65 days since 2003. As of 27 June 2024 he still owns at least 10,802,138 units of Kronos Bio stock.
You can see the complete history of Dr Bischofberger stock trades at the bottom of the page.
Dr. Norbert W. Bischofberger Ph.D. is the Pres, CEO & Director at Kronos Bio.
As the Pres a CEO & Director of Kronos Bio, the total compensation of Dr D at Kronos Bio is $596,365. There are 1 executives at Kronos Bio getting paid more, with Jorge F. DiMartino M.D., Ph.D. having the highest compensation of $765,105.
Dr D is 65, he's been the Pres a CEO & Director of Kronos Bio since . There are no older and 10 younger executives at Kronos Bio.
Norbert's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger a Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: